PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day
|
|
- Ashlyn Ramsey
- 6 years ago
- Views:
Transcription
1 PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day Dr. Jim Gimlett, Program Manager DARPA Biological Technologies Office (BTO) January 30, 2018 Arlington, VA
2 PREEMPT Agenda Proposers Day Objectives PREEMPT Program Motivation and Overview PREEMPT Program Objectives PREEMPT Technical Areas Timeline and Milestones Proposal Guidance Disclaimer: In the event of a disagreement between the contents of the BAA and the information in this briefing, please follow the BAA. No exceptions. 2
3 PREEMPT Proposers Day Objectives Introduce the science and technology community (industry, academia, and government) to the PREventing EMerging Pathogenic Threats program vision and goals Explain the general mechanics of a DARPA program and the specific objectives and milestones of this program Encourage and promote teaming arrangements among organizations with the expertise, research facilities, and capabilities needed to execute research and development responsive to PREEMPT program goals 3
4 PREEMPT Vision: Far-forward biosurveillance and preemptive countermeasure pipeline DOD Problem: Military personnel deployed to areas at high risk of endemic and emerging diseases SOF deployments Low risk High risk Overlay of 2016 US SOF troops global deployment and bathuman virus risk map (Brierley et al., 2016) Fact: Most infectious diseases came from animals or are transmitted by insect vectors DARPA Goal: Eliminate viral threat surprise Preemptively block new outbreaks by targeting animal viruses before they emerge in humans Reservoirs Vector X X X Warfighter 4
5 Emerging infectious diseases: A growing threat to the DOD and to national security US Army hospital admissions during war The problem is not getting better: Higher rate of pathogen emergence due to increasing human-animal contact, population density, globalization Limited or no countermeasures for many emerging pathogens Potential for major US impact pathogens can spread rapidly, cause significant morbidity and mortality, be weaponized Source: US Army, 1999 Historically, more hospital admissions from infectious diseases than from combat injuries in deployed US forces Especially at risk: deployed active and reserve military, humanitarian operations, field troops Recent examples: Ebola, SARS, MERS, Nipah, Influenza HxNy, Chikungunya, Zika New proactive, preemptive approaches are needed 5
6 Background the path to viral species jump and emerging threats to humans Reservoir Intermediary reservoir or vector Human Stochastic bottleneck Stochastic bottleneck Viral Quasispecies (QS) Jump enabler mutation adapts to new host and expands Jump enabler mutation adapts to new host and expands 75% of human viruses started in animals To successfully jump into humans, a virus must clear several hurdles (e.g., cell entry, different host immune response, transmission bottlenecks) Viral diversity via development of quasispecies (QS) is key jump enabler Replicating virus will mutate to further adapt to new host Target viral evolution and bottlenecks to preempt species jump 6
7 PREEMPT Technical Areas A path to preempting new biological threats TA1: Develop models that quantify the likelihood of virus jump Use far-forward field surveillance data and lab data to quantify viral dynamics, evolutionary trajectories and mutations that enable species jump Identify bottleneck targets for intervention and prevention TA2: Develop and validate method(s) for species jump preemption Develop and test new approaches to suppress species jump in reservoirs Develop and test new approaches to suppress viral transmission via mosquitoes 7
8 TA1: Quantify likelihood of virus jump Field Initial viral quasispecies (t=0; QS 0 ) Lab tests Time series data & Deep sequencing Analysis Prior knowledge: known jump events; ecology, season, geospatial Validate Bat sample QS 1 QS 2 QS 3 Pig cell lines Virus competition, evolution dynamics Train Model (Data-driven) Virus QS 0 Pig sample Mosquito sample Human cell lines Human cell lines * * * * Mutations Fitness landscapes Classifier: Jump risk Low Predict: QS 0 jump risk to humans High Terraforma Animal models TA1 deliverables: Integrated models that establish likelihood of virus jump to humans Stochastic models quantifying bottlenecks (transmission, cell entry, infection rate) and mutational fitness maps to guide preemptive intervention strategy 8
9 TA1 Metrics Data source Objectives Parameters to be quantified & metrics Case study examples: Ebola, SARS, Nipah Longitudinal sampling in bat cave t=0 QS 0 =? t=6 mo QS 6mo =? t=12 mo QS 12mo =? Field surveillance Quantify viral QS in selected highrisk areas (e.g. bat cave) and/or from prior outbreak event Frequency QS reservoir =? Qs human =? Mutation Multi-species lab test data Integration of field & lab data Quantify QS for cell entry and adaptation across species in vitro Quantify transmission factors and QS adaptation between two species in vivo in contained, bio secure facilities Develop model to quantify the probability of viral species jump Develop model to identify enabler mutations and targets to preempt species jump Bat sample Case study examples (reservoir): Ebola, SARS, Nipah QS 1 QS 2 QS 3 Pig / human cell lines QS infected host =? QS bat =? QS pig/human cells =? Case study examples (vector): Dengue, Zika, Chikungunya Rate of infection vs. viremia Amplification rates Incubation time Longitudinal QS diversity QS mosquito (gut/head) =? QS transmision =? N virions (transmitted)=? Validate model accuracy to within +/- 50% in terraforma multispecies environment in contained, bio secure facilities Predict top 3 targets to reduce probability of transmission between two species by >5X; targets to be validated in TA2 9
10 TA2: Develop block-before-jump methods 1. Reduce viral entrance into new host species Virus QS harvested from reservoir/vector Single mutation identified at high risk to jump to human cells * CRISPR/Cas * Targeted gene degradation Human cell CRISPR/Cas treatment of reservoir/vector specifically removes mutant from pool 2. Reduce amount of virus in carrier or reservoir Virus QS harvested from reservoir/vector Multiple mutations identified as high-risk for jump to human cells Human cell Reduce virus in reservoir/vector using anti-virals, vaccines, interfering particles TA2 deliverables: Proof of concept preemptive intervention platform that reduces the probability of virus species jump 10
11 TA2 Metrics Data source Class of species jump Potential block-beforejump approach Parameters to be quantified within vector or reservoir Metrics of success Crossspecies lab models Single enabler mutation * * Specific targeting of enabler mutation to suppress species jump (e.g. CRISPR/CAS, RNAi, specific antibodies) Virus incubation extended >3X Virus amplification rate reduced >3X Probability of crossspecies jump reduced >5X mutation Viral genome Multiple enabler mutations ** * * ** * * Non-specific targeting of highrisk viruses within host or vector (e.g. TIP-like interference, antiviral peptide) Viremia reduced >5X Viral incubation time extended >3X Probability of crossspecies jump reduced >5X Reservoir Vector Species1 Species2 Species1 Species2 11
12 Vision of a deployable preemptive capability Leverage ongoing surveillance systems PACOM, SOUTHCOM, CENTCOM, AFRICOM Experimental testing Deep seq analysis of sample Input to model and classifier * * * * Model: Predict imminent risk of transmission to humans and best preemptive strategies Block-before-jump capability platform Generate pipeline for rapid rollout of preventive measures Preemption targets Entry into human cells Propagation of enabler mutants Viremia Transmission to/from reservoirs or vectors Focus on areas at high risk for viral jump Samples obtained from biosurveillance hotspots Predict whether virus QS has imminent potential to jump to human and identify reservoir/vector targets for preemption * * * * Suppress high-risk jump-enabling mutations within QS 10
13 Program Structure and Timeline Phase I: 24 months Phase II: 18 months TA1 Quantify probability of virus jump Deep sequence far-forward biosurveillance samples in selected high-risk regions Develop experimental and theoretical models for species jump Identify intervention opportunities, strategies Model of viral amplification Intra- and cross-species transmission models Integrated model for risk assessment and preemption TA2 Block-beforejump platform Develop platform to deter, redirect viral evolution from species jump Develop scalable reservoir inoculation technologies Develop scalable vector inoculation Validate in reservoir Validate in vector Milestones 12M Identify signatures of fitness and spillover potential of a pathogen between two species 24M Develop initial risk classifier; predict pathways of adaptation; test initial intervention approaches 42M Demonstrate capability to suppress viral jump to a new species in the lab 13
14 Proposal guidance Read the BAA carefully! For all Technical Areas: Justify virus candidate/s, animal reservoirs, and hotspots selected for study Summarize key innovations, how your approach advances beyond current practice Back up your idea and technical approach (e.g. by theoretical arguments, models, past results, new data) Provide quantitative metrics feasible within the proposed timeline Summarize key expected outputs and deliverables 14
15 Proposal guidance continued Proposers must present a plan to address both Technical Areas It is anticipated that teaming will be necessary to meet the goals of this program. Tips for teaming: Listen to presenters during today s attendee presentation sessions, where attendees will briefly present their expertise and capabilities Reach out to colleagues and collaborators 15
16 Some advice Read the BAA, carefully and respond accordingly Some instructions are specific required and must Most of the instructions are non-specific you decide on what is the best possible science to support the objectives of the program Be honest about risks and demonstrate thoughtful consideration for how to mitigate those risks Ask for clarification as needed. FAQs will be updated regularly Take advantage of today s opportunities to meet potential teammates and ask questions 16
17 PREEMPT 17
INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) Proposers Day
INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) Proposers Day Dr. Jim Gimlett, Program Manager DARPA Biological Technologies Office (BTO) April 28, 2016 Arlington, VA INTERCEPT Agenda INTERCEPT
More informationMapping the Global Virome. Making the Unknown Known. And the World Safe From a Future of Viral Threats
Mapping the Global Virome Making the Unknown Known. And the World Safe From a Future of Viral Threats If you know your enemies and know yourself, you will not be imperiled in a hundred battles;..if you
More informationWHO s code of conduct for open and timely sharing of pathogen genetic sequence data during outbreaks of infectious disease
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 WHO s code of conduct for open and timely sharing of pathogen genetic sequence data during outbreaks of infectious
More informationChikungunya Vaccines in the Pipeline
Chikungunya Vaccines in the Pipeline Health impact Public health burden : 1.3 billion people live in areas endemic for Chikungunya. Prevalent in ~60 countries over the world Has high attack rates and the
More informationIdentifying, Preparing for & Reducing Pandemic Risk
Identifying, Preparing for & Reducing Pandemic Risk Jonna Mazet, DVM, MPVM, PhD Professor of Epidemiology & Disease Ecology One Health Institute School of Veterinary Medicine University of California,
More information7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities
7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly
More informationPage 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect
More informationBlueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens WORKSHOP ON PRIORITIZATION OF PATHOGENS
Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens WORKSHOP ON PRIORITIZATION OF PATHOGENS 8-9 December 2015 Executive summary On 8-9 December,
More informationThe Current Status of the Epidemiologic Transition
The Current Status of the Epidemiologic Transition There are still job opportunities in Infectious Diseases and Tropical Medicine CAPT John W. Sanders, Medical Corps, US Navy Commanding Officer, Naval
More informationDARPA-BAA Frequently Asked Questions
DARPA-BAA-16-42 Frequently Asked Questions Last Updated: 7/19/2016 (Version 3) New Questions highlighted GENERAL INFORMATION Q: If my research is relevant in this field, but is not geared specifically
More informationA modelling programme on bio-incidents. Submitted by the United Kingdom
MEETING OF THE STATES PARTIES TO THE CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION 29 July 2004
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
More informationThe EUA Process at CDC Michael W. Shaw, PhD
The EUA Process at CDC Michael W. Shaw, PhD Office of Infectious Diseases DECLARATION OF EMERGENCY OR THREAT JUSTIFYING EMERGENCY USE Before FDA may issue an EUA, the HHS Secretary must declare that circumstances
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationProgress report on emerging and re-emerging diseases including dengue and dengue haemorrhagic fever
Regional Committee for the Eastern Mediterranean Sixty-third session Provisional agenda item 3(c) EM/RC63/INF.DOC 2 Rev.2 September 2016 Introduction Progress report on emerging and re-emerging diseases
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationEvaluating the promise of a transmissible vaccine. Scott L. Nuismer
Evaluating the promise of a transmissible vaccine Scott L. Nuismer Effective vaccines exist for 24 infectious diseases of humans Vaccines have had amazing successes Eradicated smallpox Driven polio to
More informationEmerging & re-emerging infections on the African Continent-the Public Health Aspect: Is Africa Prepared?
Emerging & re-emerging infections on the African Continent-the Public Health Aspect: Is Africa Prepared? International Conference on (Re) Emerging Infectious Diseases, 12-14 March, African Union Commission,
More informationOPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES
OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES Dr. Robert P. Kadlec Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services 2017 Chemical and
More informationEPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL?
8 th International Conference GLOBAL HEALTH CONSORTIUM Building Alliances in Global Health Miami, May 22-25, 2018 EPIDEMICS AND PANDEMICS: PREDICTION, PREVENTION, CONTROL? José Esparza MD, PhD - Adjunct
More informationRisks of Emerging Infectious Diseases in ASEAN. Prasit Palittapongarnpim, M.D. Department of Microbiology, Faculty of Science, Mahidol University
Risks of Emerging Infectious Diseases in ASEAN Prasit Palittapongarnpim, M.D. Department of Microbiology, Faculty of Science, Mahidol University Despite the socio-economic progress of ASEAN and increased
More informationAddressing climate change driven health challenges in Africa
Addressing climate change driven health challenges in Africa Ednah N Ototo, Parasitologist, Climate Change and Health Kenyatta University, Kenya Kenya Medical Research Institute Outline The impact of climate
More informationAvian influenza Avian influenza ("bird flu") and the significance of its transmission to humans
15 January 2004 Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans The disease in birds: impact and control measures Avian influenza is an infectious disease
More informationCIDRAP Leadership Forum Infectious Disease BRIEFING
Center for Infectious Disease Research and Policy University of Minnesota CIDRAP Leadership Forum Infectious Disease BRIEFING December 13 th, 2017 CLF BRIEFING HOT TOPICS 1. Influenza (surveillance, vaccine,
More informationIMPLEMENTATION OF THE NAGOYA PROTOCOL AND PATHOGEN SHARING: PUBLIC HEALTH IMPLICATIONS
CBD Distr. GENERAL UNEP/CBD/NP/COP-MOP/2/INF/12 6 December 2015 ENGLISH ONLY CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY SERVING AS THE MEETING OF THE PARTIES TO THE NAGOYA PROTOCOL
More informationFAO component of the USAID EPT-2 programme
AGENDA FAO component of the USAID EPT-2 programme Working meeting on risk modeling and assessment Rome, Italy 28-30 June 2016 28 June Tuesday 09:00 09:10 Welcome and introduction of participants J. Lubroth
More informationKiller Viruses: The Why and The How. Amesh Adalja
Killer Viruses: The Why and The How Amesh Adalja MD @AmeshAA Disclosures Stockholder: Merck, Luminex, Evolent Bondholder: UPMC Speaker s Bureau: Merck, Roche Consultant: Roche Funding: Open Philanthropy
More informationSecond intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network
Summary report on the Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network WHO-EM/CSR/070/E Sharm el-sheikh, Egypt 24 27 November 2013 Summary
More informationConfronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA
Confronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA Technical Advisor, United States Agency for International Development (USAID) Chair, WONCA Working
More informationZika Virus Response Planning: Interim Guidance for District and School Administrators in the Continental United States and Hawaii
Zika Virus Response Planning: Interim Guidance for District and School Administrators in the Continental United States and Hawaii Summary What is already known about this topic? Zika virus is transmitted
More informationUniversity of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009
University of Colorado Denver Pandemic Preparedness and Response Plan April 30, 2009 UCD Pandemic Preparedness and Response Plan Executive Summary The World Health Organization (WHO) and the Centers for
More informationCDC s Global Disease Detection Program
CDC s Global Disease Program Scott F. Dowell, MD, MPH Division of Global Disease and Emergency Response Centers for Disease Control and Prevention Rationale for Global Disease It would be extremely naïve
More informationLesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease
URI CMB 190 Issues in Biotechnology Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease 1. The film Contagion: (A) entirely depicts a situation that could never possibly happen
More informationAppendix 3: Federal Government Agencies Involved in Immunization
Appendix 3: Federal Government Agencies Involved in Immunization Department of Health and Human Services (HHS) Secretary of Health and Human Services Directs all HHS activities. Office of the Assistant
More informationDiagnostics RDT / POC Technology for ZIKA related infections
Diagnostics RDT / POC Technology for ZIKA related infections Outline Overview of afternoon agenda Background Product Landscape analysis ZIKA scenarios of demand, areas of focus Lessons learnt.. ZIKA diagnostic
More informationEvents detected by national surveillance system (see Annex 1)
WHA58.3 ANNEX 2 DECISION INSTRUMENT FOR THE ASSESSMENT AND NOTIFICATION OF EVENTS THAT MAY CONSTITUTE A PUBLIC HEALTH EMERGENCY OF INTERNATIONAL CONCERN Events detected by national surveillance system
More informationEmerging global health threats of animal origin
Emerging global health threats of animal origin Ahmed El Idrissi Senior Officer Transboundary Animal Diseases and zoonoses Animal Production and Health Division FAO - Rome 9 th meeting of the REMESA JPC
More informationDengue Stephen J. Thomas, MD Director, Viral Diseases Branch Walter Reed Army Institute of Research (WRAIR) 14 AUG 2012
Dengue Stephen J. Thomas, MD Director, Viral Diseases Branch Walter Reed Army Institute of Research (WRAIR) 14 AUG 2012 Dengue Lecture Outline Dengue Virus Dengue Epidemiology Military Significance Clinical
More informationDisease Prevention, Detection & Response During Public Health Emergencies
Centers for Disease Control and Prevention Disease Prevention, Detection & Response During Public Health Emergencies Tom Frieden, MD, MPH Director, Centers for Disease Control and Prevention Global Disaster
More informationCenters for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary
Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is
More informationProliferation Threats from Biotechnology: What is Dual-Use Research?
Proliferation Threats from Biotechnology: What is Dual-Use Research? In Class Discussion Break into groups of 3, come up with definition dual use and present to class Biological Dual-Use Research Biotechnology
More informationDuane J. Gubler, ScD Professor and Founding Director, Signature Research Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore
Duane J. Gubler, ScD Professor and Founding Director, Signature Research Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore AGENDA Other arboviruses with the potential for urban
More informationProduct Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
More informationGlobal Catastrophic Biological Risks
Global Catastrophic Biological Risks Working Definition of Global Catastrophic Biological Risks (GCBRs) Events in which biological agents whether naturally emerging or reemerging, deliberately created
More informationThe Influence of Climate Change on Insect. Director Australian Animal Health Laboratory, Geelong
The Influence of Climate Change on Insect Borne Diseases (1) Professor Martyn Jeggo Professor Martyn Jeggo Director Australian Animal Health Laboratory, Geelong The problem the risk of infectious disease
More informationSession 44 PD, Pestilence: Getting to Know the Fourth Horseman. Moderator: Jean Marc Fix, FSA, MAAA. Presenters: Martin Meltzer, Ph.D.
Session 44 PD, Pestilence: Getting to Know the Fourth Horseman Moderator: Jean Marc Fix, FSA, MAAA Presenters: Jean Marc Fix, FSA, MAAA Martin Meltzer, Ph.D. SOA Antitrust Disclaimer SOA Presentation Disclaimer
More informationENHANCING AFRICA S PUBLIC HEALTH RESPONSE THROUGH INNOVATION AND PARTNERSHIPS
ENHANCING AFRICA S PUBLIC HEALTH RESPONSE THROUGH INNOVATION AND PARTNERSHIPS Strategic plan for the Africa CDC March 24-25, 2017 The Ebola outbreak underscored the fact that 2 pandemics are not just a
More informationSecond China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security
Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security May 17-19 2017, Wuhan, China Meeting Program Note: Each report will take 25 minutes including
More informationVIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks
INFLUENZA VIROLOGY OF INFLUENZA Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks PATHOGENICITY High pathogenicity avian influenza (HPAI) Causes severe disease in poultry
More informationZika Virus. Report to the Standing Committee on Health. Dr. Graham Sher Chief Executive Officer, Canadian Blood Services
Dr. Graham Sher Chief Executive Officer, Services Dr. Dana Devine Chief Medical and Scientific Officer, Services Services Services is an arm s-length organization within the larger health-care system of
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More information4.3.9 Pandemic Disease
4.3.9 Pandemic Disease This section describes the location and extent, range of magnitude, past occurrence, future occurrence, and vulnerability assessment for the pandemic disease hazard for Armstrong
More informationMaintaining a Safe and Adequate Blood Supply in the Event of Pandemic Influenza. Guidelines for National Blood Transfusion Services
Maintaining a Safe and Adequate Blood Supply in the Event of Pandemic Influenza Guidelines for National Blood Transfusion Services 19 May 2006 1 Rationale Current global concern that an occurrence of pandemic
More informationInfluenza Virologic Surveillance Right Size Project. Launch July 2013
Influenza Virologic Surveillance Right Size Project Launch July 2013 1 Today s Discussion Outline General Influenza Surveillance Right Size Rationale Roadmap o Requirements o Implementation o Sample Size
More informationUSDA APHIS One Health Initiative
Biorisk Management in a One Health World USDA APHIS One Health Initiative Joseph F. Annelli, DVM, MS One Health Coordination Center U.S. Department of Agriculture Animal and Plant Health Inspection Service
More informationNavigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1. Does my country need JE vaccine?
Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1 Does my country need JE vaccine? 1 about this guide Japanese encephalitis (JE), a viral infection of the
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationPreparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do
Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services
More informationOpportunities for the Future of Healthcare and Public Health Preparedness, Response, and Recovery
Opportunities for the Future of Healthcare and Public Health Preparedness, Response, and Recovery National Academy of Medicine Workshop March 8-9, 2017 Tom Inglesby Healthcare system that can care for
More informationModeling the Effects of HIV on the Evolution of Diseases
1/20 the Evolution of Mentor: Nina Fefferman DIMACS REU July 14, 2011 2/20 Motivating Questions How does the presence of HIV in the body changes the evolution of pathogens in the human body? How do different
More informationPARALLEL SESSION 2.4
PARALLEL SESSION 2.4 CHANGING DYNAMICS: EMERGING INFECTIOUS DISEASES AND ANTIMICROBIAL RESISTANCE IN AN ERA OF EXPANDING GLOBAL HUMAN POPULATION GROWTH AND MOVEMENT BACKGROUND The global human population
More informationHealth Task Force Workplan
2006/SOM 3/HTF/021 Agenda Item: VI Health Task Force Workplan 2006-2007 Purpose: Information Submitted by: Chair Health Task Force Meeting Da Nang, Viet Nam 14 15 September 2006 APEC HEALTH TASK FORCE
More informationFigure 1. Iterative process that defines the CHeRI research agenda
5 year Strategic Plan for CHeRI Samantha M. Wisely, Director Cervidae Health Research Initiative UF Institute of Food and Agricultural Sciences 11 December 2016 Executive Summary Deer farming is one of
More informationUVRI ACHIEVEMENTS BY: EDWARD K. MBIDDE, DIRECTOR- UVRI
UVRI ACHIEVEMENTS BY: EDWARD K. MBIDDE, DIRECTOR- UVRI OUTLINE PRESENTATION Historical perspective Vision, Mission, Core values Functions of UVRI and achievements HISTORIC PERSPECTIVE Established in 1936
More informationThe role of National Influenza Centres (NICs) during Interpandemic, Pandemic Alert and Pandemic Periods
The role of National Influenza Centres (NICs) during Interpandemic, Pandemic Alert and Pandemic Periods INTRODUCTION National Influenza Centres (NICs) are the backbone of the WHO Global Influenza Surveillance
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationArbovirus Surveillance in Massachusetts 2016 Massachusetts Department of Public Health (MDPH) Arbovirus Surveillance Program
INTRODUCTION Arbovirus Surveillance in Massachusetts 2016 Massachusetts Department of Public Health (MDPH) Arbovirus Surveillance Program There are two mosquito-borne diseases of concern for transmission
More informationCenter for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home
Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public
More informationVisual and Decision Informatics (CVDI)
University of Louisiana at Lafayette, Vijay V Raghavan, 337.482.6603, raghavan@louisiana.edu Drexel University, Xiaohua (Tony) Hu, 215.895.0551, xh29@drexel.edu Tampere University (Finland), Moncef Gabbouj,
More informationPreventing disease Promoting and protecting health
Preventing disease Promoting and protecting health STRENGTHENING VECTOR CONTROL FOR CHIKUNGUNYA AND DENGUE : CARPHA S ROLE Dr Christian Frederickson The problem Dengue continues to be a major public health
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationRisk and Benefit Analysis (RBA) of Gain of Function Research Gaps and Future Considerations
Science. Security. Strategy. Risk and Benefit Analysis (RBA) of Gain of Function Research Gaps and Future Considerations Gryphon Scientific Rocco Casagrande, PhD, Principal Investigator NAS Meeting February
More informationGlobal updates on avian influenza and tools to assess pandemic potential. Julia Fitnzer Global Influenza Programme WHO Geneva
Global updates on avian influenza and tools to assess pandemic potential Julia Fitnzer Global Influenza Programme WHO Geneva Pandemic Influenza Risk Management Advance planning and preparedness are critical
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationLinfa Wang CSIRO Australian Animal Health Laboratory (AAHL) 5740 papers. in 12 minutes?!
SARS Linfa Wang CSIRO Australian Animal Health Laboratory (AAHL) 5740 papers. in 12 minutes?! 1 Joint mission to China on Animal Reservoir of the SARS-CoV and potential transmission to humans (August 9
More informationEnding Malaria in Nigeria: The WHO Agenda
Nigeria Institute of Medical Research 2016 World Malaria Day Lecture 27 April, 2016 Ending Malaria in Nigeria: The WHO Agenda Dr Tolu Arowolo Malaria Containment Programme, WHO, Nigeria arowolot@who.int
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationUnderstanding and Confronting Emerging Disease
Understanding and Confronting Emerging Disease Michael J. Buchmeier, PhD. Professor, Departments of Molecular Biology and Biochemistry, and Div. of Infectious Disease, Department of Medicine, UCI Deputy
More informationA UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES
A UNIQUE NETWORK OF EXPERTISE DEDICATED TO THE FIGHT AGAINST INFECTIOUS DISEASES Since 1888, date of its creation, has been committed to contain infectious diseases by working directly in regions where
More informationPandemic Influenza Preparedness and Response
Pandemic Influenza Preparedness and Response US Department of Health and Human Services Bruce Gellin, MD, MPH Director, National Vaccine Program Office The pandemic influenza clock is ticking. We just
More informationGlobal Alert and Response Against Emerging and Reemerging Infectious Diseases an Overview
63 Global Alert and Response Against Emerging and Reemerging Infectious Diseases an Overview Tomimasa SUNAGAWA Infectious Disease Surveillance Center, National Institute of Infectious Diseases 1-23-1 Toyama,
More informationFinancing international collective action for epidemic & pandemic preparedness
Financing international collective action for epidemic & pandemic preparedness Gavin Yamey MD, MPH Professor of Global Health & Public Policy Director, Center for Policy Impact in Global Health, Duke Global
More informationRe: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy
Dr. Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness & Response Department of Health and Human Services Washington, DC 20201 Re: Trust for America s Health Comments on Biennial Implementation
More informationCurrent strategies, initiatives and challenges to mitigate biorisk: Indonesia s experience
Current strategies, initiatives and challenges to mitigate biorisk: Indonesia s experience Head of Delegation HERAWATI SUDOYO MD, PHD Eijkman Institute for Molecular Biology Ministry for Research and Technology
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationPandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice
SUPPLEMENT ARTICLE Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice Julie L. Gerberding Centers for Disease Control and Prevention, Atlanta, Georgia Influenza pandemic
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationMo Salman Animal Population Health Institute, Colorado State University, Fort Collins, Colorado, , USA
Rift Valley Fever: Is the United States really at risk for introduction of RVFV? Mo Salman Animal Population Health Institute, Colorado State University, Fort Collins, Colorado, 80523-1644, USA m.d.salman@colostate.edu
More informationPandemic Influenza: Hype or Reality?
Pandemic Influenza: Hype or Reality? Leta Finch Executive Director, Higher Education Practice 2003 Arthur J. Gallagher & Co. Objectives Review key characteristics of influenza, including differences between
More informationRichmond, Virginia. Assignment Description
Infectious Diseases, Environmental Health Virginia Department of Health, Division of Environmental Epidemiology/Division of Surveillance and Investigation Richmond, Virginia Assignment Description The
More informationWhen infections go viral Zika Virus
When infections go viral Zika Virus John Fangman, MD Associate Professor of Medicine (Infectious Diseases) Senior Medical Director of Ambulatory, Medical College Physicians Medical College of Wisconsin
More informationCurrent CEIRS Program
History The influenza program at St. Jude has a long, distinguished history as a world-class leader in the study of the origins, evolution, and pathogenesis of influenza viruses. Based on this expertise,
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationIndonesia s challenges and needs in improving national capabilities for disease surveillance, detection and diagnosis and public health systems:
Indonesia s challenges and needs in improving national capabilities for disease surveillance, detection and diagnosis and public health systems: National capabilities in public health systems Indonesia
More informationOIE Collaborating Centers Reports Activities
OIE Collaborating Centers Reports Activities Activities in 2014 This report has been submitted : 2015-04-24 16:02:49 Title of collaborating centre: Emerging and Re-Emerging Zoonotic Diseases Address of
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationBefore and during influenza pandemics
before and during influenza pandemics Klaus Stöhr Department for Communicable Diseases Surveillance and Response Before and during influenza pandemics Before pandemics: interpandemic period New human influenza
More information